Table 3.
Rates of HBV screeninga by screening period
|
Characteristic |
Period 1b |
Period 2c |
Period 3d |
P valuee | |||
|---|---|---|---|---|---|---|---|
|
All patients |
Screened patients |
All patients |
Screened patients |
All patients |
Screened patients |
||
| (N = 11,833) | (N = 1754) | (N = 5703) | (N = 1037) | (N = 1152) | (N = 229) | ||
| Age, years, mean (SD) |
54.8 (13.6) |
51.6 (15.6) |
55.1 (13.4) |
53.1 (15.2) |
56.4 (13.1) |
56.1 (14.7) |
0.0001 |
| Sex, no. (%) |
|
|
|
|
|
|
|
| Female |
6702 |
731 (10.9) |
3263 |
464 (14.2) 14.22 |
643 |
110 (17.1) 17.11 |
<0.0001 |
| Male |
5131 |
1023 (20.0) 19.94 |
2440 |
573 (23.5) 23.48 |
509 |
119 (23.4) 23.38 |
0.0003 |
| Race/ethnicity, no. (%) |
|
|
|
|
|
|
|
| White |
8464 |
1269 (15.0) |
3895 |
738 (19.0) |
809 |
161 (19.9) |
<0.0001 |
| Hispanic |
1441 |
218 (15.1) |
747 |
152 (20.4) |
131 |
32 (24.0) |
<0.0001 |
| Black |
1301 |
143 (11.0) |
654 |
83 (12.7) |
137 |
21 (15.3) |
0.04 |
| Asian |
311 |
45 (14.5) |
158 |
23 (14.6) |
39 |
8 (19.4) |
0.23 |
| Other |
316 |
79 (25.0) |
249 |
41(16.5) |
36 |
7 (20.5) |
0.02 |
| US residence, no. (%) |
11,480 |
1675 (14.6) |
5499 |
997 (18.1) |
1111 |
224 (20.0) |
<0.0001 |
| HBV risk factor, no. (%) |
3412 |
572 (16.8) |
1668 |
356 (21.3) |
311 |
88 (28.3) |
<0.0001 |
| Cancer type, no. (%) |
|
|
|
|
|
|
<0.0001 |
| Solid tumorf |
9521 |
326 (3.4) |
4602 |
208 (4.5) |
908 |
47 (5.2) |
<0.0001 |
| Hematologic malignancy |
2312 |
1428 (61.8) |
1101 |
829 (75.3) |
244 |
182 (74.6) |
<0.0001 |
| Chemotherapy |
|
|
|
|
|
|
|
| Type, n (%) | |||||||
| Rituximab |
1244 |
785 (63.1) |
606 |
481 (79.4) |
127 |
94 (74.0) |
<0.0001 |
| Non-rituximab | 10,589 | 969 (9.4) | 5097 | 556 (10.9) | 1025 | 135 (13.2) | <0.0001 |
Abbreviations:HBV hepatitis B virus, SD standard deviation, US United States.
aHBV screening means that both hepatitis B surface antigen (HBsAg) test and antibody to hepatitis B core antigen (anti-HBc) test were ordered.
bFirst chemotherapy administration from 1/1/04 through 12/18/2008.
cFirst chemotherapy administration from 12/19/2008 through 9/30/2010.
dFirst chemotherapy administration from 10/1/2010 through 4/30/11.
eCochran-Armitage trend test compares screened patients vs. unscreened patients, over the 3 time periods.
fExcludes primary liver cancer.